lol, well, the biggest issue for the Nimo business proposition is YM itself, but I get where you are coming from. Nimo's biggest uphill task will be convincing doctors who so strongly (and wrongly) believe rash = efficacy that a non-rash version is effective.
That might, as you suggest, be more complicated with presumably cheaper biosimilars available around the corner. It will be an interesting situation to watch --
Equally effective, lower AE, more expensive vs Equally effective, higher AE, less expensive
Given patients REALLY hate the rash, smart marketing might win the day. That's a different bet if YM's responsible for marketing than if a more experienced company has signed on.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.